UA60231A - Готовая лекарственная форма протаминсульфата - Google Patents
Готовая лекарственная форма протаминсульфата Download PDFInfo
- Publication number
- UA60231A UA60231A UA2003054657A UA200354657A UA60231A UA 60231 A UA60231 A UA 60231A UA 2003054657 A UA2003054657 A UA 2003054657A UA 200354657 A UA200354657 A UA 200354657A UA 60231 A UA60231 A UA 60231A
- Authority
- UA
- Ukraine
- Prior art keywords
- protamine sulfate
- substance
- drug
- dosage form
- protamine
- Prior art date
Links
- 102000007327 Protamines Human genes 0.000 title claims abstract description 32
- 108010007568 Protamines Proteins 0.000 title claims abstract description 32
- 229950008679 protamine sulfate Drugs 0.000 title claims abstract description 24
- 239000002552 dosage form Substances 0.000 title abstract description 10
- 239000000126 substance Substances 0.000 claims abstract description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Inorganic materials [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N hydrochloric acid Substances Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims abstract description 11
- 239000003755 preservative agent Substances 0.000 claims abstract description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000011780 sodium chloride Substances 0.000 claims abstract description 7
- 239000007951 isotonicity adjuster Substances 0.000 claims abstract description 6
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 claims description 12
- 230000002335 preservative effect Effects 0.000 claims description 8
- 239000013543 active substance Substances 0.000 claims description 6
- 238000012876 topography Methods 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 229930003836 cresol Natural products 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 28
- 229940079593 drug Drugs 0.000 description 27
- 229960002897 heparin Drugs 0.000 description 17
- 229920000669 heparin Polymers 0.000 description 17
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 15
- 230000000694 effects Effects 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 229940048914 protamine Drugs 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 231100000419 toxicity Toxicity 0.000 description 6
- 230000001988 toxicity Effects 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 5
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 238000006386 neutralization reaction Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 230000002429 anti-coagulating effect Effects 0.000 description 2
- 230000002364 anti-haemorrhagic effect Effects 0.000 description 2
- 230000010100 anticoagulation Effects 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 239000002473 artificial blood Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- JAWMENYCRQKKJY-UHFFFAOYSA-N [3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-ylmethyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-en-8-yl]-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]methanone Chemical compound N1N=NC=2CN(CCC=21)CC1=NOC2(C1)CCN(CC2)C(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F JAWMENYCRQKKJY-UHFFFAOYSA-N 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 229940075522 antidotes Drugs 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000036471 bradycardia Effects 0.000 description 1
- 208000006218 bradycardia Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 150000001896 cresols Chemical class 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 239000003055 low molecular weight heparin Substances 0.000 description 1
- 229940127215 low-molecular weight heparin Drugs 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
Готовая лекарственная форма протаминсульфата содержит действующее вещество – субстанцию протаминсульфата, консервант – крезол, изотонический агент – натрия хлорид, вещество, корригирующее рН раствора – соляную кислоту и воду.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UA2003054657A UA60231A (ru) | 2003-05-22 | 2003-05-22 | Готовая лекарственная форма протаминсульфата |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UA2003054657A UA60231A (ru) | 2003-05-22 | 2003-05-22 | Готовая лекарственная форма протаминсульфата |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA60231A true UA60231A (ru) | 2003-09-15 |
Family
ID=74220947
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA2003054657A UA60231A (ru) | 2003-05-22 | 2003-05-22 | Готовая лекарственная форма протаминсульфата |
Country Status (1)
| Country | Link |
|---|---|
| UA (1) | UA60231A (ru) |
-
2003
- 2003-05-22 UA UA2003054657A patent/UA60231A/ru unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2363600T3 (es) | Formulación para medicamentos proteicos sin adición de seroalbumina humana (hsa). | |
| ES2912075T3 (es) | Formulación de líquido amniótico para el tratamiento de trastornos pulmonares | |
| ES2368061T3 (es) | Composiciones farmacéuticas de toxina botulínica. | |
| EP1007068B1 (en) | Process for preparing synthetic soil-extract materials and medicaments based thereon | |
| ES2965521T3 (es) | Preparación duradera de un producto inyectable de melatonina que presenta estabilidad a largo plazo | |
| CN102458451A (zh) | 血红蛋白组合物 | |
| UA123693C2 (ru) | Фармацевтическая композиция, включающая дисульфид глутатиона и с-оксид дисульфида глататиона | |
| CN101578103B (zh) | 抗生素的注射剂及其给予液 | |
| Riaz et al. | An overview of biomedical applications of choline geranate (CAGE): a major breakthrough in drug delivery | |
| EP3578566B1 (en) | Biocidal peptide and preparation based thereon | |
| CN111557938A (zh) | 一种快速损伤病毒囊膜的消毒制剂 | |
| EP2664621A1 (en) | Antiviral agent | |
| ES2287527T3 (es) | Peptidos lineales cationicos que tienen propiedades antifungicas. | |
| UA60231A (ru) | Готовая лекарственная форма протаминсульфата | |
| CZ295765B6 (cs) | Léčebný přípravek s virucidním účinkem | |
| RU2433135C1 (ru) | Интерферон, конъюгированный с полиэтиленгликолем | |
| RU2290922C1 (ru) | Средство для лечения болезней суставов | |
| WO2001078751A1 (en) | Antiviral and antibacterial pharmaceutical preparation 'armenicum' and its use for treatment of infectious diseases | |
| CZ2002264A3 (cs) | Vícedávkové kompozice na bázi erythropoietinu | |
| RU2234313C1 (ru) | Средство инактивации коронавирусов | |
| JPS62153224A (ja) | プラスミノゲン製剤 | |
| RU2392929C2 (ru) | Средство для стимуляции выброса стволовых кроветворных клеток в кровоток | |
| JPH04502901A (ja) | シーピーエフペプチド組成物およびその用途 | |
| RU2218934C2 (ru) | Препарат интерферона | |
| KR100671449B1 (ko) | 송아지의 제단백 혈액 추출물을 함유하는 점안용 액제조성물 |